Pharmacology of angioplasty and intravascular thrombolysis.
Interventional angiographic techniques are of increasing importance in the management of arteriosclerosis and its complications. Two areas of particular interest are the treatment of focal arterial stenoses by percutaneous transluminal angioplasty and the treatment of arterial thromboemboli with selective infusion of thrombolytic agents. The administration of multiple drugs, in various combinations, is a critical factor in the success of these interventions. To effectively use this new pharmacoangiography, it is important to understand both the pathophysiology of the atherosclerotic or thrombotic process being treated and the actions of the drugs used. Preserving the effect of angioplasty relies on preventing thrombus formation and preventing recurrence of the atherosclerotic obstruction. Heparin during the procedure is clearly useful for the former, and aspirin in small doses and other antiplatelet medications are indicated for the latter. The precise utility of long-term anticoagulation, of low molecular weight dextran, and of various antiplatelet regimens remains to be proven. The theoretical importance of these medications in improving long-term patency rests on the effects they have on platelet and vessel wall prostaglandins, on intimal smooth muscle cell proliferation, and on the thrombogenicity of injured arterial intima. Fibrinolytic therapy, with streptokinase and urokinase, has been used for many years. Selective intraarterial use, however, is a new and promising application. Intracoronary streptokinase infusion during acute myocardial ischemia appears to prevent or limit infarction in certain patients. Peripheral use for acute arterial occlusion, either in native vessels or in grafts, is an area of great promise. Key considerations are thrombus age, size, and location, and the status of the arterial flow proximal and distal to the obstruction.
D000800:Angioplasty, Balloon / Q000379:methods*; D000925:Anticoagulants / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000628:therapy*; D001241:Aspirin / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects*; D003911:Dextrans / Q000627:therapeutic use; D004176:Dipyridamole / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D011453:Prostaglandins / Q000627:therapeutic use; D013300:Streptokinase / Q000627:therapeutic use; D013442:Sulfinpyrazone / Q000627:therapeutic use; D013923:Thromboembolism / Q000628:therapy*; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D003911:Dextrans; D011453:Prostaglandins; D014859:Warfarin; D004176:Dipyridamole; D006493:Heparin; D013300:Streptokinase; D014568:Urokinase-Type Plasminogen Activator; D001241:Aspirin; D013442:Sulfinpyrazone